MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of an investigational
drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.